Eight devices get 515(i) data deadline changed to Feb. 14, 1998.
This article was originally published in The Gray Sheet
Executive Summary
FOUR CARDIOPULMONARY DEVICES TO RECEIVE EXTENSION OF 515(i) deadline for submission of safety and effectiveness data from August 14, 1997 to February 14, 1998. The four devices -- sorbent hemoperfusion system, artificial embolization device, cardiopulmonary bypass arterial line blood filter and cardiopulmonary bypass oxygenator -- are among eight products for which FDA is modifying the deadline for the submission of device information under section 515(i) of the Food, Drug and Cosmetic Act to Feb. 14, 1998. The agency is preparing a Federal Register notice announcing the changed deadlines.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.